Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Non-Current Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 76.32% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, up 76.32% year-over-year, with the annual reading at $3.2 million for FY2025, 76.32% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $3.2 million at Kura Oncology, up from $3.0 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $3.2 million in Q4 2025, with the low at $351000.0 in Q1 2023.
  • Average Other Non-Current Liabilities over 3 years is $1.5 million, with a median of $1.3 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities surged 170.94% in 2024, then surged 76.32% in 2025.
  • Over 3 years, Other Non-Current Liabilities stood at $705000.0 in 2023, then surged by 154.61% to $1.8 million in 2024, then soared by 76.32% to $3.2 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $3.2 million, $3.0 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.